340 related articles for article (PubMed ID: 1311061)
21. Carcinogen exposure, p53 alteration, and K-ras mutation in synchronous multiple primary lung carcinoma.
Wang X; Christiani DC; Mark EJ; Nelson H; Wiencke JK; Gunn L; Wain JC; Kelsey KT
Cancer; 1999 Apr; 85(8):1734-9. PubMed ID: 10223567
[TBL] [Abstract][Full Text] [Related]
22. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines.
Lehman TA; Bennett WP; Metcalf RA; Welsh JA; Ecker J; Modali RV; Ullrich S; Romano JW; Appella E; Testa JR
Cancer Res; 1991 Aug; 51(15):4090-6. PubMed ID: 1855224
[TBL] [Abstract][Full Text] [Related]
23. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.
Kosaka T; Yatabe Y; Endoh H; Kuwano H; Takahashi T; Mitsudomi T
Cancer Res; 2004 Dec; 64(24):8919-23. PubMed ID: 15604253
[TBL] [Abstract][Full Text] [Related]
24. [Molecular study on minute alterations of the p53 and the N-ras genes in hematologic malignancies].
Kurosawa M
Hokkaido Igaku Zasshi; 1994 May; 69(3):543-54. PubMed ID: 7927179
[TBL] [Abstract][Full Text] [Related]
25. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma.
Tomizawa Y; Kohno T; Fujita T; Kiyama M; Saito R; Noguchi M; Matsuno Y; Hirohashi S; Yamaguchi N; Nakajima T; Yokota J
Oncogene; 1999 Jan; 18(4):1007-14. PubMed ID: 10023676
[TBL] [Abstract][Full Text] [Related]
26. Molecular staging of non-small cell lung cancer according to K-ras genotypes.
Rosell R; Monzó M; Pifarré A; Ariza A; Sánchez JJ; Moreno I; Maurel J; López MP; Abad A; de Anta JM
Clin Cancer Res; 1996 Jun; 2(6):1083-6. PubMed ID: 9816271
[TBL] [Abstract][Full Text] [Related]
27. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
Shigematsu H; Takahashi T; Nomura M; Majmudar K; Suzuki M; Lee H; Wistuba II; Fong KM; Toyooka S; Shimizu N; Fujisawa T; Minna JD; Gazdar AF
Cancer Res; 2005 Mar; 65(5):1642-6. PubMed ID: 15753357
[TBL] [Abstract][Full Text] [Related]
28. p53 mutations in lung tumors: relationship to putative susceptibility markers for cancer.
Ryberg D; Kure E; Lystad S; Skaug V; Stangeland L; Mercy I; Børresen AL; Haugen A
Cancer Res; 1994 Mar; 54(6):1551-5. PubMed ID: 8137262
[TBL] [Abstract][Full Text] [Related]
29. K-ras and p53 mutations in hamster pancreatic ductal adenocarcinomas and cell lines.
Erill N; Cuatrecasas M; Sancho FJ; Farré A; Pour PM; Lluís F; Capellá G
Am J Pathol; 1996 Oct; 149(4):1333-9. PubMed ID: 8863680
[TBL] [Abstract][Full Text] [Related]
30. The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern.
Takahashi T; Takahashi T; Suzuki H; Hida T; Sekido Y; Ariyoshi Y; Ueda R
Oncogene; 1991 Oct; 6(10):1775-8. PubMed ID: 1656362
[TBL] [Abstract][Full Text] [Related]
31. Alterations of Fas (APO-1/CD 95) gene and its relationship with p53 in non small cell lung cancer.
Boldrini L; Faviana P; Pistolesi F; Gisfredi S; Di Quirico D; Lucchi M; Mussi A; Angeletti CA; Baldinotti F; Fogli A; Simi P; Basolo F; Fontanini G
Oncogene; 2001 Oct; 20(45):6632-7. PubMed ID: 11641789
[TBL] [Abstract][Full Text] [Related]
32. GSTM1, P53 and K-ras molecular detection in resectable non-small cell lung cancer by denaturing gradient gel electrophoresis-bronchoalveolar lavage fluid analysis.
Curigliano G; Ferretti G; Mandalà M; De Pas T; Calabrò MG; Solli P; Noberasc C; de Braud F
Anticancer Res; 2001; 21(5):3461-9. PubMed ID: 11848510
[TBL] [Abstract][Full Text] [Related]
33. Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung.
Kishimoto Y; Murakami Y; Shiraishi M; Hayashi K; Sekiya T
Cancer Res; 1992 Sep; 52(17):4799-804. PubMed ID: 1324794
[TBL] [Abstract][Full Text] [Related]
34. Detection of Ki-ras mutations by PCR and differential hybridization and of p53 mutations by SSCP analysis in endoscopically obtained lavage solution from patients with long-standing ulcerative colitis.
Lang SM; Heinzlmann M; Stratakis DF; Teschauer W; Loeschke K
Am J Gastroenterol; 1997 Dec; 92(12):2166-70. PubMed ID: 9399746
[TBL] [Abstract][Full Text] [Related]
35. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients.
Skaug V; Ryberg D; Kure EH; Arab MO; Stangeland L; Myking AO; Haugen A
Clin Cancer Res; 2000 Mar; 6(3):1031-7. PubMed ID: 10741731
[TBL] [Abstract][Full Text] [Related]
36. Detection of K-ras and p53 mutations in bronchoscopically obtained malignant and non-malignant tissue from patients with non-small cell lung cancer.
Lang SM; Stratakis DF; Freudling A; Ebelt K; Oduncu F; Hautmann H; Huber RM
Eur J Med Res; 2000 Aug; 5(8):341-6. PubMed ID: 10958767
[TBL] [Abstract][Full Text] [Related]
37. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
[TBL] [Abstract][Full Text] [Related]
38. A modified mutagenic PCR-RFLP method for K-ras codon 12 and 13 mutations detection in NSCLC patients.
Hatzaki A; Razi E; Anagnostopoulou K; Iliadis K; Kodaxis A; Papaioannou D; Labropoulos S; Vasilaki M; Kosmidis P; Saetta A; Mihalatos M; Nasioulas G
Mol Cell Probes; 2001 Oct; 15(5):243-7. PubMed ID: 11735295
[TBL] [Abstract][Full Text] [Related]
39. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
[TBL] [Abstract][Full Text] [Related]
40. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract.
Chung KY; Mukhopadhyay T; Kim J; Casson A; Ro JY; Goepfert H; Hong WK; Roth JA
Cancer Res; 1993 Apr; 53(7):1676-83. PubMed ID: 8453641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
